Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Ppl

<< Previous

Bullboard Posts

Next >>

Comment by indaknownewfieon Apr 21, 2020 11:26am

76 Views

Post# 30934140

RE:Ppl

You have the same access as anyone to the FDA sites correct. Because you are invested in TBP like myself you are probably looking for Pppooo1-whatever but you may not find it that way. Their approvals are for CBD at different dosages with an oil that increases bioavailability and possibly other propriety information. So TBP gave each of their names such as Caumz and Qixleef. Kalytera has kept their cards a little closer to their chest and hasnt given them names yet. The patents can all be looked up. They are there I found them.

<< Previous

Bullboard Posts

Next >>

Victoria Gold: No cyanide detected downstream since mine incident